Posted on 12/2/19
Hyperfine and Penn Medicine Announce Partnership to Image Hydrocephalus Patients
GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine Research Inc. has joined with Penn Medicine in a clinical research study of the world’s first portable, low-cost magnetic resonance imaging (MRI) system. . . .
Posted on 12/2/19
Proteostasis Therapeutics Regains Compliance with Nasdaq
Proteostasis Therapeutics, Inc. (Nasdaq:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases . . .
Posted on 11/27/19
Novartis' Latest Acquisition Of The Medicines Company Sets It Up For A Large Market
SummaryNovartis announced that it would acquire The Medicines Company for $9.7 billion or for $85 per share, which was a 25% premium from Friday's close.The acquisition . . .
Posted on 11/27/19
Deciphera: Analysis Of The Market Potential Of Ripretinib
SummaryDeciphera's lead drug ripretinib showed positive phase 3 results.We recommended the company last year, when it was trading at half the price.Currently, DCPH seems fairly valued.Looking . . .
Posted on 11/26/19
X4 Pharmaceuticals Prices $65 Million Public Offering of Common Stock
CAMBRIDGE, Mass.--(BUSINESS WIRE)--X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the research, development and commercialization of novel therapeutics for the treatment of rare . . .
Posted on 11/26/19
X4 Pharmaceuticals Announces Proposed Public Offering
CAMBRIDGE, Mass.--(BUSINESS WIRE)--X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the research, development and commercialization of novel therapeutics for the treatment of rare . . .
Posted on 11/25/19
Sekisui Diagnostics Opens $1.9 Million Bioprocess Innovation Centre
Sekisui Diagnostics' Enzyme business unveiled its new Bioprocess Innovation Centre at its site near Maidstone, Kent, UK. The new R&D facility, costing $1.9 million
Posted on 11/25/19
Why I'm Holding On to My Bristol-Myers Squibb Shares Now That the Celgene Acquisition Has Closed
Goodbye, Celgene. Hello, Bristol-Myers Squibb (NYSE:BMY).With Bristol-Myers Squibb's acquisition of Celgene closing on Wednesday, one of my favorite biotech stocks is now gone. Celgene became a . . .
Posted on 11/25/19
Covetrus: The Grown-Ups Are In Charge Now
SummaryCVET’s former CEO surprisingly stepped-down subsequent to our previous article.While we would have been fine with giving the previous CEO more time to produce results, we . . .
Posted on 11/25/19
Allena Pharmaceuticals: Rating This Stock A Buy
SummaryReloxaliase has a >80% probability of reaching commercial stage after reviewing the results of the URIROX-1 trial and the design of the URIROX-2 trial.Reloxaliase has a . . .
Posted on 11/25/19
Akebia Therapeutics: Vadadustat Approval Seems Make Or Break
SummaryAkebia Therapeutics Inc. has given investors plenty of cause for concern, reflected by a share price that has dropped from $20 to $3 since Sept. '18.Sole . . .
Posted on 11/25/19
InVivo Therapeutics Closes Public Offering of Common Stock
CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) today announced the closing of its previously announced public offering of 7,000,000 shares of its common stock, par . . .
Posted on 11/22/19
Allena Pharmaceuticals: Rating This Stock A Buy
SummaryReloxaliase has a >80% probability of reaching commercial stage after reviewing the results of the URIROX-1 trial and the design of the URIROX-2 trial.Reloxaliase has a . . .
Posted on 11/21/19
InVivo Therapeutics Announces Pricing of Public Offering of Common Stock
CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) today announced the pricing of a public offering of 7,000,000 shares of its common stock, par value $0.00001 . . .
Posted on 11/21/19
Phio Pharmaceuticals and Karolinska Institutet Expand Collaboration
Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next-generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL) therapeutic platform, announced today that . . .
Posted on 11/21/19
Immunitas Therapeutics Launches with $39 Million
BOSTON--(BUSINESS WIRE)--Immunitas Therapeutics, a single cell genomics-based drug discovery company founded by Longwood Fund, today announced a $39 million Series A financing led by Leaps by . . .
Posted on 11/21/19
Vor Biopharma and MaxCyte Announce Clinical and Commercial License Agreement
CAMBRIDGE, Mass. & GAITHERSBURG, Md.--(BUSINESS WIRE)--Vor Biopharma, an oncology company pioneering engineered hematopoietic stem cells (eHSCs) for the treatment of cancer, and MaxCyte, Inc., a global . . .
Posted on 11/21/19
Planet Fitness Prices $550 Million Securitized Financing
Planet Fitness, Inc. (NYSE: PLNT) (together with its subsidiaries, the "Company") today announced that it has priced $550 million of Series 2019-1 Class A-2 Fixed Rate . . .
Posted on 11/21/19
Phio Pharmaceuticals Closes Public Offering of Common Stock
Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced . . .
Posted on 11/21/19
Karuna Therapeutics Prices $250M Public Offering of Common Stock
BOSTON, Mass.--(BUSINESS WIRE)--Karuna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with . . .
Posted on 11/21/19
Genprex Announces $1.26 Million Registered Direct Offering
AUSTIN, Texas & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel . . .
Posted on 11/21/19
APDerm Partners with Dermatology Professionals
ACTON, Mass.--(BUSINESS WIRE)--APDerm®, a leading group of dermatology experts throughout the New England area, has acquired Dermatology Professionals, Inc. (DPI). The addition of DPI includes two . . .
Posted on 11/20/19
Werewolf Therapeutics Launches with $56M Series A Financing
Werewolf Therapeutics, an oncology biotherapeutics company advancing a pipeline of next generation, transformative cancer treatments, today announced the completion of its $56 million Series A financing.
Posted on 11/20/19
Dragonfly Therapeutics Announces Collaboration with AbbVie
Dragonfly Therapeutics, a biotechnology company developing novel immunotherapies that harness the innate immune system to treat disease, and AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, . . .
Posted on 11/20/19
Cardurion Pharmaceuticals Announces Investment from Polaris Partners
BOSTON--(BUSINESS WIRE)--Cardurion Pharmaceuticals, a biotechnology company focused on the development of novel, next-generation therapeutics for the treatment of heart failure and other cardiovascular diseases, today announced . . .

